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Male hormonal contraception 
A B S T R A C T   
Nowadays, conscious planning of the family is very important for many people. The possibility of using pro-
tective measures against unplanned pregnancy is a great comfort. Most forms of contraceptives are intended for 
women, although their use can be ruled out in various health conditions. Scientists have been trying to develop a 
different type of method for men for many years. More and more research is being done and there have been 
promising results. It is hoped that soon both genders will have a similar range of contraceptive options to enable 
responsible family planning.   
Introduction 
For many years, contraception has allowed men and women to 
consciously plan families and decide about the possibility of having a 
child. Making decisions about your own body is a basic human right. The 
history of contraception began in ancient times, where women placed 
various substances of a slightly acidic nature, or physical barriers, into 
the vagina to prevent sperm from entering the uterus. As time pro-
gressed, newer and more advanced methods of contraception for women 
appeared. In 1838, the first reports of a barrier method appeared, which 
consisted of applying a cap to the cervix. In 1881, the first surgery for 
female sterilization was described. As science progressed, work 
continued on hormonal methods of preventing pregnancy, and in 1957, 
the results of a clinical study conducted on oral contraception were 
published, and in 1959, a product appearing on the market.1 Many more 
female contraceptive methods have been developed since then, with the 
most popular being female sterilization and intrauterine devices, and the 
pill and injection agents being slightly less so. In 2015, nearly 64% of 
women were using some method of contraception. Fig. 1 is presenting 
estimates of contraceptive prevalence by method among married or in- 
union women aged 15 to 49 (percentage) from 2015.2 
The history of male contraception is much shorter. The oldest 
method of contraception currently used by men is the condom. There are 
reports that the first versions were being used in ancient Egypt3; how-
ever, the first documented reports about condoms come from 1564 
published by Gabriello Fallopio, in which they were described as a 
method of preventing syphilis infection. Until 1844, condoms were 
made from the intestines of animals such as sheep or goats. They had 
some disadvantages, one of which was their high price. However, pro-
duction costs were reduced by the use of rubber, following the discovery 
of vulcanisation in 1844, and the condom gained popularity in the 
1870s.4 Production switched to latex after 1930s3; however, this is not 
an ideal substance, as approximately 4.3% of men and women may be 
allergic to latex.5 Two types of allergic reactions can occur: type I - 
anaphylaxis and type IV - hypersensitivity. Symptoms may include 
itching, coughing, chest tightness, shortness of breath and wheezing. 
However, later discoveries led to the use of plastic and polyurethane in 
condom production.3 
Another well-known method of controlling male fertility is vasec-
tomy. There are two types of this procedure: irreversible and reversible 
vasectomy. All vasectomy procedures aim to close the vas deferens.6 
Although the first vasectomy was performed to cause prostate atrophy, it 
was later acknowledged as a full-fledged contraception method during 
the Second World War.7 One of the newest, and most effective, methods 
is no-scalpel vasectomy.8 However, there are continual efforts to iden-
tify possible improvements to this procedure. 
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Between 2011 and 2015 in the US, 60% of unmarried men aged 15 to 
44 in the US surveyed reported having used a male form of contracep-
tion during their last sexual intercourse, the most common being a 
condom.9 On the other hand, in a 2004 study, 55% of the surveyed men 
from 4 different continents expressed their willingness to use new 
methods of contraception for men. Interestingly, most of them showed 
the greatest interest in the drug in the form of a once-a-day orally taken 
pill (only in Indonesia was the once-a-month injection more popular). 
Fig. 2 is presenting percentage of men interested in using a new method 
of male contraception from 2004.10 
Another study providing valuable data is the satisfaction with the use 
of male contraception in the form of a transdermal gel (with testosterone 
and nestorone). It was shown that out of 79 respondents, 44 were 
satisfied with this form of the drug and as many as 26 would use it as the 
main method of preventing unwanted pregnancy.11 So we can see an 
upward trend in men’s interest in a new form of contraception for them. 
In the period 2010–2014, about 44% of pregnancies were unin-
tended12 which could mean that contraception was not used, or that it 
did not fulfil its role. Nevertheless, as the responsibility for pregnancy 
arguably lies with both women and men. Both sexes should have access 
to a similar range of contraceptive options. Despite this, male contra-
ception methods remain the minority constituting only 21% of all used 
contraception methods in 2015.2 However, there are implications that 
new male contraceptives may be of great significance in preventing 
unwanted pregnancy. This is particularly important in countries where 
the percentage of contraceptive use is low (40%); in Africa, only 33% of 
women of reproductive age use some form of contraception, and the 
introduction of new methods may encourage their wider use.2,13 This 
may well result in a decrease in the number of unwanted pregnancies, 
thus potentially improving quality of life and wellbeing: the unintended 
birth rate decreased by 27% in developing countries between 1990–94 
and 2010–14.12 Hence, a great deal of research is currently underway on 
possible male hormonal or non-hormonal method of contraception. 
In spermatogenesis, haploid spermatozoa are formed as a result of 
meiotic division from spermatogonia. The process is governed by go-
nadotropins, more specifically FSH (follicle stimulating hormone) and 
LH (luteinizing hormone, which causes Leydig cells to produce testos-
terone, which is needed for the proper course of spermatogenesis), these 
being peptide hormones produced by the pituitary gland following 
stimulation by gonadoliberin produced by the hypothalamus. They also 
affect the development of sexual characteristics and fertility.14 The 
current paper reviews possible forms of male contraception and the 
results of the latest research on this subject. 
Hormonal contraception 
Currently, many types of male contraception are being worked on, 
one group of options being oral formulations. Dimethandrolone (7α, 
11β-dimethyl-19-nortestosterone) undecanoate (DMAU) is a compound 
which offers great promise. It is administered to the patients in the form 
of an ester and is then metabolised in the body to DMA (Dimethan-
drolone). After 28 days of oral administration, a decrease in plasma LH 
(luteinizing hormone), responsible for the proper functioning of the 
interstitial cells of the testes in which testosterone is produced, FSH 
(follicle-stimulating hormone), responsible for stimulating sperm pro-
duction and increasing the production of androgen-binding protein 
(ABP), and testosterone levels was noticed, which affected male fertility. 
Participants receiving 400 mg DMA in powder and 400 mg with castor 
oil/benzyl benzoate per day demonstrated lower concentrations of LH 
and FSH (<1.0 IU/L) and serum T level (<50 ng/dL). After seven days of 
taking DMAU, a significant decrease in the levels of gonadotropic hor-
mones and testosterone (median < 24 ng/dL) produced in the body were 
found to fall. DMA binds to receptors for progesterone and androgens 
located in the pituitary and hypothalamus, thus inhibiting the secretion 
of pituitary hormones that affect testicular hormonal activity, i.e. the 
hypothalamus from secreting GnRH and the pituitary from secreting LH 
and TSH, via negative feedback.15 
An analysis of the form of DMA administration found all delivery 
methods to be effective; however, increased conversion of dimethan-
drolone undecanoate to dimethandrolone was noticed for castor oil and 
the self-emulsifying drug delivery system. Their effectiveness as poten-
tial contraceptives for men can be improved by increasing ester hydro-
lysis. In addition, its metabolism is also dependent on the fat content 
taken with meals: taking this compound on a diet high in fat (50% 
calories as fatty substances) increases ester hydrolysis, making it a more 
effective treatment. Moreover, only administration of DMAU (7α,11β- 
dimethyl–19-nortestosterone undecanoate) by the self-emulsifying drug 
delivery system was found to be reasonably effective under fasting 
conditions.16 
11β-Methyl-19-Nortestosterone17β-dodecylcarbonate (11β-MNTDC) 
is another substance tested for use as oral male contraception. It is a 
prodrug in the form of an ester that is converted in vivo into the active 
substance: 11β-methyl-19-nortestosterone. Like DMA, it inhibits the 
secretion of androgens by binding to androgen and progesterone 
Fig. 1. Estimates of contraceptive prevalence by method among married or in-union women aged 15 to 49 (percentage), 2015. 2  
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receptors. Taking this substance with food was found to significantly 
increase its serum concentration. Doses of 200, 400 and 800 mg effec-
tively reduced sex hormone levels. No reduction in FSH concentration 
was observed, and significant suppression of luteinizing hormone was 
observed only at the 200 mg dose. Interestingly, already after a single 
intake of 11b-MNTDC with food, a decrease in plasma testosterone was 
noticed.17 However side effect of long-term oral 11β-MNTDC use is 
decreased libido and erectile dysfunction in patients. Out of 42 re-
spondents, five reported a decrease in sex drive, and three reported 
problems with erection and ejaculation. What’s more, the decrease in 
libido was more common in men taking 11β-MTDC in a dose of 200 mg 
than 400 mg. It is also worth noting that the use of 11β-MNTDC has the 
undesirable effect of a decrease in HDL-C concentration and an increase 
in LDL-C concentration in the body, most with the oral use of a dose of 
400 mg. With parenteral administration, this disorder is less noticeable. 
Researchers suspect that this is due to the “first pass effect”, that is, in 
large part, the drug is excreted via metabolic pathway in liver before it 
enters the systemic circulation, especially when taken orally. However, 
in order to accurately determine the risk of developing cardiovascular 
diseases, we still need further research on this effect of 11β-Methyl-19- 
Nortestosterone17β-dodecylcarbonate.18 
An alternative form of using hormonal contraception are injections 
of norethisterone enanthate (200 mg) and testosterone undecanoate 
(1000 mg). After 24 weeks (one dose every eight weeks) participants 
demonstrated a decrease in sperm concentration to ≤ 1 million/ml, and 
a significant decrease in serum level LH and FSH, compared to the re-
sults obtained before treatment initiation. Fifty-two weeks after injec-
tion, sperm concentration returned to ≥ 15 million/ml. Which indicates 
the potential reversibility of this method. Moreover, 75% of participants 
were satisfied with this method. Unfortunately, side effects have also 
been reported,including: mood disorders, increased libido, and acne.19 
Another study examining the effectiveness of the combination of 
testosterone and progesterone derivatives compared four different sub-
stances (levonorgestrel, cyproterone acetate, norethisterone acetate all 
taken orally and Nestorone®- progestin taken through the skin) with a 
combination of transdermal exogenous testosterone. The greatest sup-
pression of FSH and LH production occurred in patients who were taking 
cyproterone acetate and levonorgestrel together with testosterone 
administered via skin. Significantly, the reduction of gonadotropic 
hormone concentration by progesterone is exacerbated by the trans-
dermal application testosterone (LH < 0.5 IU/L and FSH < 0.5 IU/L). 
The authors note that such research is needed to determine the mini-
mum effective dose of progesterone derivatives in order to reduce 
adverse reactions. 20 
The use of these testosterone and LH-lowering preparations in 
teenage boys is a problematic issue, as the reduced levels of the above- 
mentioned hormones in adolescents can cause serious side effects such 
as sexual development problems, decreased testicular weight, gyneco-
mastia, and disturbed body proportions in favour of body fat and 
disadvantage of muscle tissue. 21 
Summarizing, the benefits of male hormonal contraception include 
among others its reversibility and a variety of forms of administration. 
Unfortunately, this is not an ideal method of preventing undesirable 
pregnancy, because apart from side effects such as a negative effect on 
the lipid metabolism, decreased libido, mood disorders, acne, adoles-
cents should not take them due to potential sexual development 
disorders. 
Mechanical methods 
Male fertility can not only be controlled by hormonal drugs. Me-
chanical methods which offer the advantage of not influencing the 
hormonal balance can also be used. One of the most promising drugs 
may be RISUG ® (Reversible inhibition of sperm under guidance). This 
styrene and maleic anhydride copolymer22 injected into the vas deferens 
lowers the pH level and creates a positive charge, thus preventing the 
proper transport of male reproductive cells through the female repro-
ductive tract.23 In albino rats, zero animal fertility was observed 90 days 
after RISUG injection. Interestingly, this method is reversible, by 
injecting solvents such as DMSO (dimethyl sulphoxide) or NaHCO3. 
Restoration of fertility varied depending on the solvent used: satisfac-
tory fertility after 45 days for DMSO, and after 30 days for NaHCO3. No 
serious tissue changes (testis cells of Rattus norvegicus) were observed 
after use for less than a year; however, focal degeneration was noticed in 
the group in which occlusion of the vas lasted for 360 days without 
DMSO or NaHCO3 reversal. More research is needed to confirm the 
safety of this procedure.22 This preparation was also found to be effec-
tive in rabbits with no serious side effects. A complete absence of sperm 
in the ejaculate was noted after 30–60 days. Sperm concentration 
returned to normal 135–150 days after DMSO or NaHCO3 treatment.24 
VasalGel™ a styrene-alt-maleic acid (SMA) polymer with a high 
molecular (360 kDa) weight can also be injected. It acts as a barrier 
through which spermatozoa cannot pass through. It can be removed by 
DMSO. This preparation has already been tested on rabbits and rhesus 
monkeys. Studies show that this method is also very effective but more 
research is needed to determine its absolute safety. 23 
It has also been proposed that ultrasound with frequency range of 8 
Hz to 22 kHz may serve as a means of contraception for men by reducing 
the mobility and viability of sperm cells, and slowing their movement 
into the epididymis. 25 This appears to be a cheap and reversible method. 
Fig. 2. Percentage of men interested in using a new method of male contraception (2004).10  
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Chemical contraception 
Many preliminary but promising studies exist on potential chemical 
contraceptives. It has been found that the number of spermatozoa may 
be reduced by disrupting the synthesis of retinoic acid. This can be 
achieved by inhibiting the ALDH1A2 enzyme in human germ cells, 
which is a catalyst for the conversion of retinaldehyde to retinoic acid. 
Currently, this method has been tested on zebrafish, using WIN 18,446, 
i.e. bis-(dichloroacetyl)-diamine as an inhibitor – Fig. 3. 
However, further research and the discovery of more possible 
ALDH1A2 inhibitors are needed. 26 
Another target may also be the pan-retinoic acid receptor α isoform. 
By inhibiting this receptor, scientists achieved inhibition of spermato-
genesis in mice, and this effect was reversible, but requires further 
research to determine its potential use in humans. 27 
Other studies have examined the effect of glycogen synthase kinase- 
3-α (GSK3α), found inter alia in sperm cells, and calcineurin. The former 
is known to be responsible for the regulation of transcription factors and 
sperm protein phosphatase. Spermatozoa without the GSK3α exhibit 
impaired motility and are unable to enter the state hyperactivation that 
is needed for conception. Mice lacking sperm-specific calcineurin (PP2B- 
protein phosphatase 2, type B) demonstrate impaired sperm maturation 
and mobility. A noticeable correlation between the quality of sperm and 
the amount of these enzymes may be key to discovering a new path for 
male contraception. 28 
BrdT protein is a potential target for non-hormonal male contra-
ception. These are the domains involved in the recognition of tran-
scriptional regulatory proteins among others in spermatogenesis 
because they are specific for the testes. The search for inhibitors spe-
cifically targeting this protein may have a significant impact on the 
development of research work on effective male contraception. 29 
CatSper channels are sperm-specific. They regulate the concentration 
of calcium ions in the intracellular space, thus influencing sperm 
motility, making them a promising target for a new male contraception. 
Researchers found that RU-1968F1 (steroid structure –Fig. 3) is an in-
hibitor of these channels and is not sperm-toxic. Promising results 
indicate the possible use of this compound in a non-hormonal new male 
pregnancy preventive measure. 30 
The α-4 subunit of Na, K-ATPase is a potential grip site for non- 
hormonal contraceptives. The sodium–potassium pump is a protein 
responsible for the transport of sodium ions outside the cell and potas-
sium into the cell interior using energy from ATP hydrolysis. It is 
composed of 4 α subunits and 3 β subunits. The alpha-4 subunit is a 
potential target of male contraception as it is present in the testes and 
expressed in spermatids and spermatocytes. Animal studies have shown 
that administration by oral gavage of ouabain derivatives (including 
compound 25 – Fig. 3) to rats resulted in, inter alia, reduced sperm 
motility and hyperactivated motility that is necessary to fertilize the 
ovum. 31 
Another promising method of male contraception is the use of epinn 
inhibitors. It is a protein found on the surface of sperm. When ejacula-
tion occurs, the protein binds to semogelin1 (SEMG1), which leads to the 
inability of sperm motility. This is temporary, however, as this binding is 
hydrolyzed by the protein-specific antigen (PSA), leading to regaining 
motility by male reproductive cells. Compounds against Eppin are being 
developed to prevent it from binding to SEMG1. One of them is EP055, 
which has shown very promising results in animals during research. 
After administration as an infusion (at a dose of 75–80 mg / kg), a sig-
nificant decrease in sperm motility was observed and this effect was 
reversible.32,33 
As science progresses, the number of potential targets for male 
contraception grows that does not focus on the effects on the hormonal 
balance of patients. Among them there are:  
• Serine protease 55 (Prss55), which is testis-specific and in the 
absence of it, the infertility of the tested animals was demonstrated 34  
• Calcium- and integrin-binding protein 4 (CIB4), highly expressed in 
the testes, which plays a significant role in shaping the upper region 
of the sperm head. During the studies, it was shown that mice lacking 
this protein were sterile. 35  
• Transmembrane serine protease 12 (Tmprss12), strongly expressed 
in the testes, contributes to the possibility of sperm migration in the 
woman’s reproductive tract. It has been proven that the inactivity of 
this protein results in infertility. 36  
• Testis-specific serine kinase (TSSK) is a group of proteins that are 
expressed in sperm and are strongly associated with the differenti-
ation of male reproductive cells. Animals lacking these proteins were 
confirmed to be infertile. 37,38  
• Kallikrein-related peptidases (KLKs) are enzymes responsible for 
liquefying (via SEMG hydrolysis) of the ejaculate after ejaculation- 
the sperm becomes mobile enough to fertilize the egg. Reversible 
sterility can be achieved by inhibiting these proteins. 39 
Clinical trials 
Currently, four preparations with potential use in male contraception 
are under evaluation in clinical trials. In one study (NCT00161447), a 
group of men aged 18 to 55 years were given three drugs: Testim, Depo- 
Medroxyprogesterone and Acyline. Two study groups were formed; the 
first was given only Testim and Depo-Medroxyprogesterone, while the 
second was administered all three drugs. This combination was aimed at 
inhibiting the production of gonadotropic hormones and thus sper-
matogenesis. An important point of the study was the addition of the 
gonadoliberin antagonist, which accelerated and intensified the whole 
process. These studies reached phase II. Sperm concentration was found 
to drop significantly over the course of administration among the men 
who were given testosterone and medroxyprogesterone acetate: sperm 
counts were 72 ± 29 million per ml at the beginning of the study, while 
57% had<100,000 sperm per ml. after 12 weeks, and 86% in 24 week . 
However, in patients receiving all three drugs, the mean sperm count 
was 68 ± 46 million per ml at the beginning of the study, and 65% of the 
group had<100,000 sperm per ml after 12 weeks, and 76% after 24 
weeks. The two groups demonstrated similar times to reach the original 
concentration of sperm following treatment. In addition, there were very 
few side effects in the study group. This offers promise as a potential 
male contraceptive. 40 
In another clinical trial (NCT01382069), patients were administered 
dimethandrolone undecanoate (DMAU). In the first part of the study, the 
doses were increased to determine the degree of safety and oral dose 
tolerance for healthy men. Volunteer recruitment is currently underway 
for the second part of the study. The study is still in phase I.15,16 Fig. 3. Chemical structures the most important compounds.  
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Study (NCT03298373) have also been conducted in Los Angeles 
Biomedical Research Institute at Harbor-UCLA Medical Center (Tor-
rance, California, United States) and University of Washington Medical 
Center & Health Sciences (Seattle, Washington, United States) to 
determine the safety and tolerability parameters of 11-β Methyl Nor-
testosterone Dodecylcarbonate for healthy men. Similarly, in phase I, 
increasing doses of the preparation will be administered for 28 days to 
determine whether 11β-MNTDC is a safe form of contraception. 
Recruitment is still ongoing (in Phase IIb), for international clinical 
trial (NCT03452111) in which Nestorone® and Testosterone Combina-
tion Gel will be administered to patients via the transdermal route. It is 
planned to administer the drug daily for 12 months and examine the 
sperm concentration to see if it has fallen enough to prevent conception 
during sexual intercourse. Interestingly, pairs will be recruited, and 
consultations will be conducted every month with the man, and every 
third with the woman to more identify possible side effects. 
Finally, another study (NCT02927210) in Los Angeles Biomedical 
Research Institute at Harbor-UCLA Medical Center (Torrance, Califor-
nia, United States) and University of Washington Medical Center & 
Health Sciences (Seattle, Washington, United States) is examining the 
potential of Dimethandrolone Undecanoate given as injection. The study 
is currently in the recruitment phase and is expected to be completed in 
October 2020. This is the first phase of the study and, as in the previous 
case, the safety and degree of tolerance, pharmacokinetics and phar-
macodynamics of the DMAU will be examined. 
Conclusions 
Many methods of male contraception are under investigation, but 
their results are promising. A number options are being considered to 
improve patient comfort and effectiveness. The search for new potential 
non-hormonal grip points for male contraceptives is a very important 
direction in which we should follow due to the lack of drug interference 
with the hormonal balance of the human body. Continued research has 
already yielded positive results, and these offer hope that varied con-
traceptive methods for men will soon be widely available. 
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